Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.
Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check19 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the location details.SummaryDifference3%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedSeveral key resources related to genetics and rare diseases have been removed, including links to MedlinePlus and NIH, which may impact access to important health information.SummaryDifference5%
- Check48 days agoChange DetectedThe website has been updated to version 2.12.2, adding several new resources related to genetics, lung cancer, and drug information, while removing the previous version 2.12.1.SummaryDifference5%
- Check55 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.1%
- Check63 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential improvements or features.SummaryDifference0.2%
Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.